Medline Inc. Class A Common Stock (MDLN)vsResMed Inc (RMD)
MDLN
Medline Inc. Class A Common Stock
$45.32
+2.56%
HEALTHCARE · Cap: $37.84B
RMD
ResMed Inc
$207.81
-0.77%
HEALTHCARE · Cap: $29.87B
Smart Verdict
WallStSmart Research — data-driven comparison
Medline Inc. Class A Common Stock generates 413% more annual revenue ($28.43B vs $5.54B). RMD leads profitability with a 27.4% profit margin vs 4.1%. RMD trades at a lower P/E of 19.8x. RMD earns a higher WallStSmart Score of 73/100 (B).
MDLN
Buy52
out of 100
Grade: C-
RMD
Strong Buy73
out of 100
Grade: B
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+68.8%
Fair Value
$144.24
Current Price
$45.32
$98.92 discount
Margin of Safety
-13.4%
Fair Value
$228.91
Current Price
$207.81
$21.10 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Earnings expanding 1258.0% YoY
Strong operational efficiency at 35.3%
Safe zone — low bankruptcy risk
Every $100 of equity generates 25 in profit
Keeps 27 of every $100 in revenue as profit
Areas to Watch
Premium valuation, high expectations priced in
ROE of 6.5% — below average capital efficiency
4.1% margin — thin
Negative free cash flow — burning cash
No major concerns identified
Comparative Analysis Report
WallStSmart ResearchBull Case : MDLN
The strongest argument for MDLN centers on EPS Growth. Revenue growth of 14.8% demonstrates continued momentum.
Bull Case : RMD
The strongest argument for RMD centers on Operating Margin, Altman Z-Score, Return on Equity. Profitability is solid with margins at 27.4% and operating margin at 35.3%. Revenue growth of 10.8% demonstrates continued momentum.
Bear Case : MDLN
The primary concerns for MDLN are P/E Ratio, Return on Equity, Profit Margin. Thin 4.1% margins leave little buffer for downturns.
Bear Case : RMD
No major red flags identified for RMD, but monitor valuation.
Key Dynamics to Monitor
MDLN profiles as a value stock while RMD is a mature play — different risk/reward profiles.
MDLN is growing revenue faster at 14.8% — sustainability is the question.
RMD generates stronger free cash flow (520M), providing more financial flexibility.
Monitor MEDICAL INSTRUMENTS & SUPPLIES industry trends, competitive dynamics, and regulatory changes.
Bottom Line
RMD scores higher overall (73/100 vs 52/100), backed by strong 27.4% margins and 10.8% revenue growth. MDLN offers better value entry with a 68.8% margin of safety. Both earn "Strong Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Medline Inc. Class A Common Stock
HEALTHCARE · MEDICAL INSTRUMENTS & SUPPLIES · USA
Medline Inc. manufactures med-surg products serving the hospital, surgery centers, physician offices, post-acute facilities, and nursing home sites of care in the United States and Internationally. The company is headquartered in Northfield, Illinois.
Visit Website →ResMed Inc
HEALTHCARE · MEDICAL INSTRUMENTS & SUPPLIES · USA
ResMed is a San Diego, California-based medical equipment company. It primarily provides cloud-connectable medical devices for the treatment of sleep apnea (such as CPAP devices and masks), chronic obstructive pulmonary disease (COPD), and other respiratory conditions.
Visit Website →Compare with Other MEDICAL INSTRUMENTS & SUPPLIES Stocks
Want to dig deeper into these stocks?